Blueprint Medicines BPMC reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Blueprint Medicines beat estimated earnings by 10.44%, reporting an EPS of $-2.23 versus an estimate of $-2.49.
Revenue was up $41.79 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.45 which was followed by a 6.06% increase in the share price the next day.
Here's a look at Blueprint Medicines's past performance:
Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
---|---|---|---|---|
EPS Estimate | -2.23 | -1.94 | -1.65 | -1.63 |
EPS Actual | -2.68 | -1.79 | -0.99 | -2 |
Revenue Estimate | 37.24M | 36.65M | 102.69M | 42.47M |
Revenue Actual | 36.55M | 62.73M | 107.02M | 24.19M |
To track all earnings releases for Blueprint Medicines visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.